Botanical New Drug
Innovation for dermatology
Botanical new drugs are developed by extracting natural active ingredients from plants, undergoing rigorous scientific experiments and clinical trials to ensure their quality, safety, and efficacy, ultimately resulting in medications for the prevention or treatment of diseases.
SCROLL DOWN
New Drug Development Progress
New Drug Development Progress
GM-XANTHO
Indications：Atopic Dermatitis
GM-XANTHO stands out as the world's only botanical drug for atopic dermatitis.
Phase I
Phase II
Phase III
2021 Mar
GM-XAN002
Indications：Pressure Ulcer
In experimental validation using a pressure ulcer mice model, GM-XAN002 has been shown to reduce wound inflammation, promote epidermal regeneration, stimulate granulation tissue formation, and facilitate angiogenesis, aiding in the healing of pressure ulcer wounds.
Pre-Clinical
IND
Phase I
2021 Nov
GM-XAN003
Indications：Plaque Psoriasis
GM-XAN003 has been confirmed to reduce the epidermal thickness of psoriatic mice and improve symptoms such as inflammation and scaling. US IND approval was obtained in March 2022, and Phase IIa trials are anticipated to be initiated in Q1 of 2027.
Pre-Clinical
IND
Phase I
2022 Mar
GM-XAN005
Indications：Diabetic Wound
GM-XAN005 has completed preclinical experiments, demonstrating its efficacy in treating wounds in diabetic rats. It is anticipated that the application for US IND will be submitted in Q4 2024.
Project Initiation
Pre-Clinical
IND
2025 Feb
GM-XAN006
Indications：Burn Wounds
GM-XAN006 has completed preclinical experiments, demonstrating its ability to accelerate the wound healing process in burn-injured rats.
Project Initiation
Pre-Clinical
IND
1
5
Project Initiation
Pre-Clinical
IND
Phase I
Phase II
Phase III
Market
2021 Mar
Project Initiation
Pre-Clinical
IND
Phase I
Phase II
Phase III
Market
2021 Nov
Project Initiation
Pre-Clinical
IND
Phase I
Phase II
Phase III
Market
2022 Mar
Project Initiation
Pre-Clinical
IND
Phase I
Phase II
Phase III
Market
2025 Feb
Project Initiation
Pre-Clinical
IND
Phase I
Phase II
Phase III
Market
-
GM-XANTHO
-
GM-XAN002
-
GM-XAN003
-
GM-XAN005
-
GM-XAN006
About us
Innovation, Excellence, Trust, and Sustainability.
Xantho Bio., established in 2014, focuses on developing botanical new drugs with low side effects. We aims to develop topical treatments for long-term use, offering physicians and patients alternatives to topical steroids and immunosuppressants.
Botanical New Drug
Xantho Bio. is dedicated to treating skin diseases, developing niche medications suitable for all age groups to enhance quality of life.
Immunity & inflammation
GM-XANTHO is a topical use botanical new drug for treating atopic dermatitis, with Phase II clinical trials expected to be completed in Q1 2025.
News & Events
News
MORE
Attended BIO 2024 for global business partnering
Xantho Bio.participated in the BIO2024 in San Diego US, from June 3 to June 6, 2024, as part of the Taiwan delegation.
June 2024
Exhibition
MORE
GM-XANTHO Phase 2a Clinical Progress
GM-XANTHO Phase 2a Clinical Progress Has Reached 80%.
April 2024
News
MORE
Congrats! Taiwan Patent has been granted
Patent of GM-XANTHO for burn wound and diabetic wound have been granted in Taiwan in Sep 2023 .
October 2023
News
MORE
Congrats! India Patent has been granted
Patent of GM-XANTHO has been granted by Directorate General of Intellectual Property(DGIP) in India in Apr 2023.
April 2023
News
MORE
Clinical Phase I in Taiwan
On Nov, 2019, Xantho Bio. successfully obtained a permit of IND from Taiwan TFDA. Completed Phase I on Jan 2021. Conduct clinical Phase IIa on Apr 2021 in NTUH.
April 2021
News